ClinicalTrials.gg
CompletedNCT04820595PoDUpdated Jul 11, 2023

Postoperative Neurocognitive Dysfunction: Is There Any Place for Emergency Agitation: A Prospective Cohort Trial

An observational study in Emergence Delirium, Emergence Agitation and Postoperative Delirium, sponsored by Negovsky Reanimatology Research Institute. Completed at 2 sites in Russian Federation. Open to participants aged 45 Years to 74 Years. Per ClinicalTrials.gov, last updated 2023-07-11.

Sponsored by Negovsky Reanimatology Research Institute · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
45 Years to 74 Years
Sex
All
01

Study summary

Perioperative neurocognitive disorders (PND) have been studying by clinicians, particularly by anesthesiologists, pretty long, however the most inspiring advancements were achieved during the last few decades. The most recent classification of PND which includes cognitive decline diagnosed before operation (described as neurocognitive disorder); any form of acute event (postoperative delirium) and cognitive decline diagnosed up to 30 days after the procedure (delayed neurocognitive recovery) and up to 12 months (postoperative neurocognitive disorder) was proposed in 2017. However at will one can notice at least one uncertainty that pertinent to the definition of delirium, emergency delirium and not mentioned in the classification discussed agitation.

The objective of the study is to determine if there is a difference between emergence agitation and emergence delirium.

02

Conditions studied

  • Emergence Delirium
  • Emergence Agitation
  • Postoperative Delirium

Keywords

  • emergence agitation
  • postoperative agitation
  • postoperative delirium
  • postoperative cognitive dysfunction
  • emergence delirium
03

In context

Emergence Delirium

753 studies on the registry are indexed under Emergence Delirium; 261 are open to participants now.

This study's enrollment of 200 is above the median of 164 across 278 observational studies indexed under Emergence Delirium.

Browse Emergence Delirium studies →

Lead sponsor

Negovsky Reanimatology Research Institute is the lead sponsor of 10 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients from 45 to 74 years old undergoing elective orthopedic surgery

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age from 45 to 74 years
  • Undergoing elective orthopedic surgery
  • Provide written to participate in the PoD trial

Exclusion criteria

Exclusion Criteria:

  • Undergoing emergent/urgent surgery
  • \< 18 points
  • History of mental disorders according ICD-11
  • Treated with at least one psychotropic drug
  • Patients with neuromuscular disease
  • Inability to undergo preoperative assessment for any reason
  • Previously enrolled in PoD trial
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (actual)
Patient registry
No

Groups and cohorts

  • Control group

    Patients who have RASS \< +2 and have not delirium according CAM-ICU immediately upon emergence from anesthesia

    Diagnostic Test: RASS · Diagnostic Test: CAM-ICU

  • Agitated non-delirious group

    Patients who have RASS = +2 or more and have not delirium according CAM-ICU immediately upon emergence from anesthesia

    Diagnostic Test: RASS · Diagnostic Test: CAM-ICU

  • Agitated delirium group

    Patients who have RASS = +2 or more and have delirium according CAM-ICU immediately upon emergence from anesthesia

    Diagnostic Test: RASS · Diagnostic Test: CAM-ICU

Interventions

  • Diagnostic testRASS

    Richmond Agitation-Sedation Scale

  • Diagnostic testCAM-ICU

    Confusion Assessment Method for the ICU

06

What researchers measure

Primary outcomes

  1. frequency of postoperative delirium

    Percent of postoperative delirium

    Time frame: 5 postoperative day

  2. frequency of postoperative cognitive dysfunction

    Percent of postoperative cognitive dysfunction

    Time frame: 7 postoperative day

Secondary outcomes

  1. frequency of emergence agitation

    Percent of emergence agitation

    Time frame: immediately upon emergence from anesthesia

  2. frequency of emergence delirium

    Percent of emergence delirium

    Time frame: immediately upon emergence from anesthesia

  3. Length of postoperative delirium

    Day of the end of postoperative delirium - day of onset of postoperative delirium

    Time frame: 5 postoperative day

  4. Length of stay in ICU

    From ICU admission to ICU discharge

    Time frame: 1 year

  5. Length of hospitalization

    From operative day to hospital discharge

    Time frame: 1 year

  6. MACE

    Cardiac death or Myocardial infarction or Non-fatal cardiac arrest or Coronary revascularization

    Time frame: 30 day

  7. MACE

    Cardiac death or Myocardial infarction or Non-fatal cardiac arrest or Coronary revascularization

    Time frame: 1 year

  8. MACCE

    Cardiac death or Myocardial infarction or Non-fatal cardiac arrest or Coronary revascularization or Cerebrovascular accident

    Time frame: 30 day

  9. MACCE

    Cardiac death or Myocardial infarction or Non-fatal cardiac arrest or Coronary revascularization or Cerebrovascular accident

    Time frame: 1 year

  10. 30-day mortality

    30-day mortality

    Time frame: 30 day

  11. 1-year mortality

    1-year mortality

    Time frame: 1 year

07

Study locations

2 sites
  • Moscow Scientific Clinical Center
    Moscow, 111123, Russian Federation
  • Main Military Clinical Hospital n.a. Acad.N. N. Burdenko
    Moscow, Russian Federation
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Jun 2022, 14 months.

Of 180 non-industry observational studies under Emergence Delirium, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 14 months is below that.

Counting every sponsor, half of 180 studies reached it within 21 months; a quarter within 10 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2021
First posted
Mar 29, 2021
StartActual
Mar 30, 2021
Primary completionActual
Jun 9, 2022
CompletionActual
Jun 9, 2023
Last update
Jul 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04820595
Lead sponsor
Negovsky Reanimatology Research Institute
Responsible party
Valery Likhvantsev, MD (Head of the Research Negovsky Reanimatology Research Institute, Negovsky Reanimatology Research Institute) — Principal investigator
First posted
Mar 29, 2021
Start date
Mar 30, 2021
Primary completion
Jun 9, 2022
Completion
Jun 9, 2023
Last update
Jul 11, 2023

Study contacts

Valery Likhvantsev
principal investigator · Negovsky Reanimatology Research Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion